metformin and everolimus

metformin has been researched along with everolimus in 26 studies

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's19 (73.08)24.3611
2020's7 (26.92)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Steinman, TI1
Eucker, J; Habbel, P; Liu, H; Possinger, K; Regierer, AC; Schefe, JH; Scholz, C; Schulz, CO; Zang, C1
Akahori, H; Finn, AV; Habib, A; Karmali, V; Pachura, K; Polavarapu, R1
De Loof, H; De Meyer, GRY; Martinet, W1
Carlock, C; Chen, J; Chen, JS; Choi, HH; Chou, PC; Ensor, J; Esteva, FJ; Fraser Symmans, W; Fuentes-Mattei, E; Gully, C; Hortobagyi, GN; Lee, MH; Luo, Y; McKeehan, WL; Phan, L; Pusztai, L; Qi, Y; Shin, JH; Velazquez-Torres, G; Wu, Y; Yeung, SC; Zhang, F; Zhang, Y; Zhao, R1
Beijnen, JH; Huitema, AD; Opdam, FL; Schellens, JH1
Galani, V; Georgiou, I; Kitsou, C; Kosmas, IP; Lazaros, L; Markoula, S; Mynbaev, O; Peschos, D; Prapas, I; Prapas, N; Tournaye, H; Zikopoulos, A1
Weintraub, K1
Fan, C; Li, L; Sun, Y; Wang, Y; Wei, J1
Buzzoni, R; Concas, L; de Braud, F; Femia, D; Formisano, B; Giacomelli, L; Leuzzi, L; Marceglia, S; Mazzaferro, V; Milione, M; Pusceddu, S; Vernieri, C1
Desir, S; Dickson, EL; Geller, MA; Lou, E; Steer, CJ; Subramanian, S; Teoh, D; Thayanithy, V; Vogel, RI; Wong, P1
Ariaans, G; Jalving, M; Jong, S; Vries, EG1
Klümpen, HJ; Mathot, RA; Molenaar, RJ; Richel, DJ; van de Venne, T; Weterman, MJ; Wilmink, JW1
Savage, N1
Alfonso, F; Cequier, Á; Cubero-Gallego, H; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Jiménez-Quevedo, P; Montanya, E; Pinar, E; Romaguera, R; Roura, G; Sabaté, M; Tebé-Codorni, C; Teruel, L1
Antonuzzo, L; Aroldi, F; Bajetta, E; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Buzzoni, R; Campana, D; Carnaghi, C; Catena, L; Cauchi, C; Cavalcoli, F; Cingarlini, S; Colao, A; Concas, L; Davì, MV; de Braud, F; De Divitiis, C; Delle Fave, G; Di Costanzo, F; Di Maio, M; Duro, M; Ermacora, P; Faggiano, A; Fazio, N; Femia, D; Fontana, A; Garattini, SK; Giacomelli, L; Giuffrida, D; Ibrahim, T; La Salvia, A; Lo Russo, G; Marconcini, R; Massironi, S; Mazzaferro, V; Milione, M; Ortolani, S; Panzuto, F; Perfetti, V; Prinzi, N; Puliafito, I; Pusceddu, S; Razzore, P; Ricci, S; Rinzivillo, M; Spada, F; Tafuto, S; Torniai, M; Vernieri, C; Zaniboni, A1
Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ1
Broaddus, RR; Coleman, RL; Fellman, BM; Iglesias, DA; Lu, KH; Slomovitz, BM; Soliman, PT; Westin, SN; Yates, MS; Yuan, Y; Zhang, Q1
Goodwin, PJ; Madariaga, A; Oza, AM1
Borson-Chazot, F; Forestier, J; Hue-Fontaine, L; Lemelin, A; Lombard-Bohas, C; Milot, L; Raverot, G; Robinson, P; Walter, T1
Chen, MJ; Chen, SU; Chou, CH; Ho, HN; Huang, CC; Shun, CT; Wen, WF; Yang, YS1
Endo, I; Haba, S; Hara, K; Hasegawa, S; Hosono, K; Ichikawa, Y; Kato, S; Kessoku, T; Kobayashi, N; Kubota, K; Kurita, Y; Kuwahara, T; Mizuno, N; Nakajima, A; Niwa, Y; Okuno, N; Sato, T; Shimizu, Y; Tokuhisa, M1
Han, WK; Hong, SH; Hwang, HJ; Lee, KS; Park, SY; Yoon, YE1
Asghari, F; Karimi, MH; Pourfathollah, AA1

Reviews

4 review(s) available for metformin and everolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Polycystic kidney disease: a 2011 update.
    Current opinion in nephrology and hypertension, 2012, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan

2012
mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Absorbable Implants; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Dyslipidemias; Everolimus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Macrophages; Metformin; Mice; Mice, Knockout; Plaque, Atherosclerotic; Rabbits; Receptors, LDL; Rupture, Spontaneous; Sirolimus; Swine; Tissue Scaffolds; TOR Serine-Threonine Kinases; Triglycerides

2014
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
    Future oncology (London, England), 2016, Volume: 12, Issue:10

    Topics: Antineoplastic Agents; Comorbidity; Diabetes Mellitus; Everolimus; Humans; Hypoglycemic Agents; Metformin; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms

2016

Trials

3 trial(s) available for metformin and everolimus

ArticleYear
A phase Ib study of everolimus combined with metformin for patients with advanced cancer.
    Investigational new drugs, 2018, Volume: 36, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Neoplasms; TOR Serine-Threonine Kinases

2018
In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients.
    Revista espanola de cardiologia (English ed.), 2018, Volume: 71, Issue:11

    Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug Synergism; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Male; Metformin; Prospective Studies; Prosthesis Design; Time Factors; Tomography, Optical Coherence; TOR Serine-Threonine Kinases; Treatment Outcome

2018
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Investigational new drugs, 2019, Volume: 37, Issue:2

    Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate

2019

Other Studies

19 other study(ies) available for metformin and everolimus

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Anticancer research, 2012, Volume: 32, Issue:5

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Autophagy; Breast Neoplasms; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Everolimus; Female; Humans; Metformin; Sirolimus; TOR Serine-Threonine Kinases

2012
Metformin impairs endothelialization after placement of newer generation drug eluting stents.
    Atherosclerosis, 2013, Volume: 229, Issue:2

    Topics: Angioplasty, Balloon; Animals; Disease Models, Animal; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Hypoglycemic Agents; Iliac Artery; Immunosuppressive Agents; Male; Metformin; Paclitaxel; Rabbits; Sirolimus; Thrombosis; Tubulin Modulators

2013
Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:7

    Topics: Adipocytes; Adipokines; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Everolimus; Female; Humans; Kaplan-Meier Estimate; Metformin; Mice; Mice, Transgenic; Middle Aged; Obesity; Postmenopause; Prospective Studies; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcriptome

2014
[Hyperglycaemia during treatment with everolimus].
    Nederlands tijdschrift voor geneeskunde, 2014, Volume: 158

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Neoplasm Recurrence, Local; Sirolimus; TOR Serine-Threonine Kinases

2014
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2015, Volume: 31, Issue:9

    Topics: AMP-Activated Protein Kinases; Animals; Capillary Permeability; Chorionic Gonadotropin; Erlotinib Hydrochloride; Everolimus; Female; Follicle Stimulating Hormone; Hormones; Infliximab; Metformin; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Reproductive Control Agents; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha

2015
Can We Stop Aging?
    Scientific American, 2015, Volume: 313, Issue:1

    Topics: Aged, 80 and over; Aging; Animals; Bone Morphogenetic Proteins; Chronic Disease; Everolimus; Growth Differentiation Factors; Humans; Longevity; Metformin; Sirolimus

2015
Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
    Oncology research, 2014, Volume: 22, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Activators; Everolimus; Female; Metformin; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Ribosomal Protein S6 Kinases; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays

2014
Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells.
    Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

    Topics: Antineoplastic Agents; Biological Transport; Cell Communication; Cell Line, Tumor; Cell Membrane; Coculture Techniques; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Hypoxia; Intercellular Junctions; Metformin; Microscopy, Confocal; Microscopy, Fluorescence, Multiphoton; Ovarian Neoplasms; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment

2016
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
    BMC cancer, 2017, 03-29, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Everolimus; Female; Glucose; Glycolysis; Humans; Metformin

2017
New tricks from old dogs join the fight against ageing.
    Nature, 2017, 12-14, Volume: 552, Issue:7684

    Topics: Aging; Animals; Autophagy; Biomedical Research; Caenorhabditis elegans; Cellular Senescence; Diet, Healthy; DNA Damage; Dogs; Drosophila melanogaster; Everolimus; Exercise; Health; Heart; Humans; Immunity; Life Expectancy; Longevity; Metformin; Mice; Quality of Life; Rejuvenation; Saccharomyces cerevisiae; Sirolimus; Social Support; Stress, Psychological; Telomere Shortening; TOR Serine-Threonine Kinases

2017
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Gastroenterology, 2018, Volume: 155, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Diabetes Mellitus, Type 2; Disease-Free Survival; Everolimus; Female; Humans; Hypoglycemic Agents; Italy; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Somatostatin; Time Factors; Treatment Outcome; Young Adult

2018
Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 02-01, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Everolimus; Female; Humans; Letrozole; Metformin; Middle Aged; Progression-Free Survival

2020
Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 02-01, Volume: 26, Issue:3

    Topics: Diabetes Mellitus, Type 2; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Metformin

2020
Metformin and everolimus in neuroendocrine tumours: A synergic effect?
    Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:6

    Topics: Aged; Antineoplastic Agents; Cohort Studies; Diabetes Mellitus; Digestive System Neoplasms; Drug Synergism; Everolimus; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Middle Aged; Neuroendocrine Tumors; Progression-Free Survival

2020
Metformin: a novel promising option for fertility preservation during cyclophosphamide-based chemotherapy.
    Molecular human reproduction, 2021, 01-22, Volume: 27, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cells, Cultured; Cyclophosphamide; Everolimus; Female; Fertility; Hypoglycemic Agents; Metformin; Mice; Mice, Inbred C57BL; Ovarian Follicle; Protective Agents; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53

2021
Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
    Internal medicine (Tokyo, Japan), 2023, Jan-15, Volume: 62, Issue:2

    Topics: Aged; Everolimus; Humans; Metformin; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis

2023
Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma.
    Genes, 2022, 07-06, Volume: 13, Issue:7

    Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Everolimus; Humans; Kidney Neoplasms; Metformin; Mitochondrial Dynamics; Neoplasm Recurrence, Local

2022
mTORC1 inhibition may improve T lymphocytes affected by aging.
    Immunopharmacology and immunotoxicology, 2023, Volume: 45, Issue:6

    Topics: Aged; Aging; Animals; Everolimus; Humans; Interleukin-2; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; T-Lymphocytes; TOR Serine-Threonine Kinases

2023